Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Next Previous
Trial Profile

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rasagiline (Primary) ; Pramipexole
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms ACTOR

Most Recent Events

  • 21 Jun 2012 Results presented at the 16th International Congress of Parkinson's Disease and Movement Disorders.
  • 25 May 2012 Actual patient number is 112 as reported by ClinicalTrials.gov.
  • 25 May 2012 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top